Background: This study aimed to clarify the change of the expression of placenta-specific 1 (PLAC1) in the placenta of preeclamptic women and to explore the regulatory effects on thophoblast by PLAC1.
Introduction
Preeclampsia, a disorder characterized by hypertension and proteinuria after 20 weeks of gestation and sometimes accompanied by maternal multi-organ dysfunction, affects 3% to 5% of all pregnancies, and is one of the major causes for maternal and infant mortality and morbidity in the perinatal period. [2] The pathogenesis of preeclampsia is not completely known. However, placenta plays a crucial role in the development of this complication. [2, 3] The placenta, a transient organ that connects fetus to her mother, is critical in maintaining normal pregnancy and fetal growth, and is involved in the pathogenesis of pregnancycomplicated diseases especially preeclampsia. In preeclamptic pregnancies, inappropriate spiral arterial remodeling, shadow placentation, inadequate placental perfusion and hypoxia have been observed. [3, 4] Impaired trophoblast invasion and migration are the key step for failure of spiral arteries remodeling. Proliferation of non-invading trophoblasts, excess of proliferative immature intermediate trophoblast, [5, 6] and increased trophoblast apoptosis was also noticed in preeclampticplacenta. [7] [8] [9] [10] However, the mechanisms leading to dysfunction of trophoblast in preeclampsia remains unknown. PLAC1, a gene named placenta-specific protein 1, is located at the Xq26 chromosome, which has been thought necessary in placental growth. [11] As a placenta-specific protein, PLAC1 is localized to the membranous compartment in the apical region of the syncytiotrophoblast, expresses throughout pregnancy in human placenta. [11] [12] [13] PLAC1 is essential for placental and embryonic development since PlAC1 ablation results in placentomegaly and mild intrauterine growth retardation (IUGR). [13] The knockdown of PLAC1 by RNA interference suppresses the invasion and migration of trophoblast cells, attenuates spontaneous syncytialization of primary human cytotrophoblast cells, [12] [13] [14] and shortens the distance of the outgrowth of the induced extravilloustrophoblasts (EVTs) column from the cytotrophoblast column of human placental explants. [3, 4] These findings indicate PLAC1 is essential for the invasion, migration and syncytialization of human placental trophoblast and thus Editor: Daryle Wane.
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play an important role in the placental and embryonic development.
More evidences indicated the link between PLAC1 and preeclampsia. As we described before, PLAC1 gene is on the X chromosome, a region near the HPRT locus. [11] Interestingly, the homologous Plac1 gene of mouse is located to a syntenic site on the X chromosome, which maps to the interspecific hybrid placental dysplasia (Ihpd) locus. Ihpd locus has been considered as one of the major genetic determinants for placental development. [14] Generally speaking, hypertrophy of the placenta improves fetal growth, while placental hypotrophy leads to growth defect or even death of the fetus. [1, 15] Besides, it has been showed Plac1-null mice is related to intrauterine growth retardation and has a reduced postnatal viability. [1] Very recently, PLAC1 expression was found to be inversely associated with neonatal birth weight. [16] These findings indicate that PLAC1 plays an important role in the placental development both in human and mouse.
For example, mRNA of PLAC1 can be found in maternal plasma, but dispersed rapidly after delivery. [7, 17] In addition, PLAC1 mRNA is higher in maternal plasma of preeclamtic women than the normal. [7, [18] [19] [20] However, the involvement of PLAC1 in preeclampsia has never been investigated. We hypothesized placental expression of PLAC1 may be altered in preeclampsia and this potential change may induce the dysfunction of trophoblast. To verify our hypothesis, we first determined placental levels of PLAC1 protein in women with preeclampsia and normal pregnancy. Moreover, to get insight into the role of PLAC1 in preeclampsia, we also observed the influence of PLAC1 on the functions of trophoblast.
Material and methods

Subjects
Placental tissues were collected after Caesarean section from nineteen women with normal pregnancy and 19 women with severe preeclampsia with the approval from Institutional Ethical Committee of Women's Hospital, School of Medicine, Zhejiang University and informed consents. Preeclampsia was diagnosed and classified according to the criteria recommended by ACOG, [21] and the inclusion and exclusion criteria, which were described in our previous publications. [22] 
Immunohistochemistry staining for PLAC1
For immunohistochemistry, placental tissues were immobilized in 10% formaldehyde and then transferred to paraffin. Paraffinembedded tissues were cut into 4uM of thickness, then deparaffinized in xylene, dehydrated in alcohol. They were then incubated with Anti-PLAC1 antibody, at dilution of 1:50 at 4°C for 12 hours (cat.no. Ab105395; Abcam, Cambridge, UK) and with horseradish peroxidase (HRP)-conjugated secondary antibodies (cat.no. K5007; Dako, Agilent, Denmark A/S) for 30 minutes at room temperature counterstained. Then stained with 0.5% diaminobenzidine kit with Mayer's haematoxylin (Shanghai genomics, Shanghai, China), The staining of PLAC1 were photographed using a microscope of Olympus CHK, Japan (400Â).
Western blotting
For Western blotting, placental tissues were stored at À80°C until assay. Proteins extracts (30 mg per lane) were separated on 12% sodium dodeeylsulfate-polyacrylamine gel electrophoresis (SDS-PAGE) and then transferred onto polyvinylidenedifluoride (PVDF) membranes (Millipore, Massachusetts, USA), protein concentration was detected through the BCA Protein Kit (Lianke Biotech, China). The membranes were blocked with Trisbuffered saline (TBS) containing 0.1% Tween 20 (TBST) and 5% bovine serum albumin for 1 hour at room temperature, and sequentially incubated with the primary antibodies (anti-PLAC1 antibody: ab105395; Abcam, Cambridge, UK, diluted at 1:500 in TBS/T; anti-actin, Huaan, China, diluted at 1:10000 in TBS/T) overnight at 4 o C. The membranes were washed three times with TBS/T and incubated in the TBS/T containing HRP-conjugated secondary antibody at room temperature for 1 hour. The protein bands were detected by enhanced-chemiluminescence (ECL from Fude Biotech, China) and visualized by autoradiography (ImageQuant TL Software, GE healthcare, American). The relative expression of PLAC1 was normalized against internal control b-actin.
Hypoxia analysis
Trophoblast cells were seeded in 10 cm petri dish at a density of 1Â10 6 cells/dish, and then cultured at the oxygen concentration of 21% (normoxia) or 0.4% (hypoxia) for 48 hours, respectively.
Cell culture and transfection of siRNA
Cells were cultured as previously describe. Cells were transfected with PLAC1 siRNA (Origene, catalog number: SR307335; concentration: 25 nmol/mL) or scrambled siRNA (Origene; sc37007) using LipofectamineRNAMax (Invitrogen, catalog number: 13778150, America) according to the manufacturer's protocol, and blank group was set without siRNA as control. The transfection medium was replaced with complete medium 24 hours after transfection, and the cells were incubated for further experiment. The expression of PLAC1 was determined with Western blotting as described above.
Cell proliferation assay
Cells were seeded in 96-well plates with 5000 cells per well. The medium was replaced with the corresponding serum-free medium for 24 hours to synchronize the cells, and then the culture media was replaced with complete medium at the indicated concentrations for 48 hours. Then, 10 ul solution of cell counting kit (CCK) 8 (Dojindo Inc., Kumamoto, Japan) was added, the plates were incubated for 3 hours, and absorbance was measured at 450 nm using a MRX II microplate reader (BioTek Inc., Vermont).
Cell migration and invasion assay
Cell migration and invasion were analyzed with the transwell analysis. After transfection with PLAC1 siRNA (10 nmol/mL), add 2 Â 10 5 cells in the upper chamber of a Transwell 24-insert plate with medium. For invasion assay, the upper chambers were coated with Matrigel (BD Biosciences, NJ); for migration assay, the coating of Matrigel was omitted. The lower chamber contained 10% FBS medium. After 24 hours, the bottoms of the inserts were fixed in methanol for 10 minutes and stained with hematoxylin and eosin (H&E). The cells that had invaded to the lower surface were photographed and counted using an inverted phase contrast microscope (400 Â ). 
Flow cytometric analysis of apoptosis
Swan-71 and Jar were plated in 6-well at a density of 1 Â 10 5 cells/ well for 24 hours, and then transfected with siRNA. After 48 hours of transfection, the culture medium was aspirated and the cells were quickly washed twice with ice-cold PBS, and then trypsinized. Cells were collected and re-suspended in 500 ul 1X binding buffer, then added 5 ul Annexin-V-FITC or 10 ul PI solutions (Lianke, China), and incubated for 5 minutes at room temperature in the dark. After that, the rates of apoptotic cells were determined by flow cytometer (BD Biosciences, NJ).
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate the distribution of data. Data are presented as the means ± SD of at least three separate experiments and were compared with the analysis of variance (ANOVA) or the Student t test where appropriate. SPSS statistical package (Statistical Analysis System, Chicago, IL, version 20.0) was used for the statistical analysis. Differences were considered statistically significant when P < .05. All experiments were repeated at least 3 times. Table 1 summarized the clinical data of subjects. There were no significant differences in maternal age and fetal gender between normal pregnancy (control) and severe preeclampsia. The significant differences in blood pressure and proteinuria confirmed the diagnosis of preeclampsia, while the differences in gestational age at delivery, and neonatal birth weight were due to preeclampsia. As shown in Figure 1 , IHC showed that PLAC1 was mainly expressed in the trophoblasts of placenta (A, B), and placental PLAC1 level was significantly reduced in severe preeclampsia compared with normal pregnancy ( Fig. 1 : C, D, P < .001).
Results
Hypoxia is the characteristic pathology of preeclampsia. To determine if the hypoxia affects PLAC1 expression, trophoblasts (Swan-71 and Jar) were cultured at the oxygen concentration of 21% (normal oxygen concentration) and 0.4% (low oxygen concentration) for 48 hours. We found that PLAC1 expression was significantly reduced when cultured in hypoxia condition compared with the control (Fig. 2: A, B , Swan-71: P = .018).
To detect the effect of PLAC1 in trophoblast, cells were transfected by PLAC1 siRNA. Results showed PLAC1 siRNA significantly down-regulate the PLAC1 expression both in Swan- Table 1 Clinical characteristics of patients with or without preeclampsia. and Jar (Fig. 2 : C, D, Swan-71: P = .026). PLAC1 siRNA significantly reduced the proliferation of Swan-71 and Jar ( Fig. 3 : A, Swan-71: P < .001). As shown in Figures 3 and 4 , transwell analysis revealed the lower expression of PLAC1 significantly decreased the number of Swan-71 and Jar cells that were found both on the transwell membranes with ( Fig. 3: B , C, Swan-71: P < .001) or without Matrigel coating ( Fig. 3 : D, E, Swan -71, P < .001), and also increased the apoptosis of cells ( Fig. 4: A, B , Swan-71: P = .004).
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Discussion
In the current investigation we confirmed the PLAC1 expression in human placenta and found decreased expression of PLAC1 in the placenta of women with severe preeclampsia compared with women of normal pregnancy for the first time. Hypoxia, a characteristic pathophysiology of preeclampsia, decreased PLAC1 expression by trophoblast. Further, knockdown of PLAC1 by RNA interference suppressed the proliferation, invasion and migration, furthermore, increased the apoptosis of trophoblast cells. These findings imply the decreased placental PLAC1 expression may be involved in the pathogenesis of preeclampsia. Several studies have reveled higher levels of plasma PLAC1 mRNA concentrations in preeclamptic women than control, [7, [18] [19] [20] and PLAC1 mRNA levels in maternal plasma dramatically decline at the first day after delivery, and could not be detected one month later. [7, 17] These findings suggest the placenta is the origin of PLAC1 mRNA in maternal plasma. However, we observed significantly decreased PLAC1 protein in the placenta of women with severe preeclampsia. There is a discrepancy between decreased PLAC1 protein in placenta and increased mRNA level in maternal plasma. As demonstrated in the current investigation, hypoxia, a characteristic of preeclampsia, inhibited the expression of PLAC1 in placental trophoblast. The damages of placental villi and the apoptosis are increased in preeclampsia; these are consistent with our findings. Hypoxia and oxidative stress, which are present in preeclampsia, could damage the functions of trophoblast cells. [7] However, the reason of the increased mRNA of PLAC1 in plasma is unknown.
As revealed in this study and others, PLAC1 has a critical role in promoting biological features at least including viability, migration and invasion of trophoblast cells. [23] Placentation is a highly migrate and invasive process in normal pregnancy, which the EVTs derived from the placenta migrate into the uterine wall and deeper in myometrium. [1, 15] This invasion is very important for the remodeling of spiral arteries, which makes spiral artery dilated, non-vascular activity and low resistance vessel to provide adequate nutrients and oxygen for the fetus. [24] Relatively small placenta, shadow placentation and inadequate remodeling of spiral artery are central pathologies of preeclampsia. Inhibited proliferation, migration and invasiveness and increased apoptosis are among the causes for above-mentioned preeclamptic pathophysiology. Our in vitro investigation revealed the down-regulation of RNA interference inhibited PLAC1 expression by trophoblast, while placental PLAC1 expression was decreased in preeclampsia. This points to the importance of low PLAC1 expression in the pathology of preeclampsia.
The pathophysiology of preeclampsia is much more complex than what was mentioned above. Whether aberrant placental PLAC1 level in preeclampsia has impact on other biological feature of trophoblast cells, or is associated with other pathologies of preeclampsia still need further investigation. In addition, whether the aberrant PLAC1 expression is the intrinsic feature of trophoblast cells in the setting of preeclampsia, or is induced by hypoxia as demonstrated in this study also need investigation.
The limitations of this research include relative small sample size and having no mild preeclampsia women. It is unknown whether PLAC1 is also decreased in other kinds of preeclampsia cases. Further, a larger sample size is needed to investigate the relation between PLAC1 and preeclampsia including mild and severe cases in the future.
In summary, the placental expression of PLAC1 is markedly decreased in preeclampsia, which could be induced by hypoxia, and down-regulation of PLAC1 inhibits the proliferation, migration, invasion of trophoblast, and increased the apoptosis, suggesting aberrant placental PLAC1 expression may be involved in the pathogenesis of preeclampsia.
